William Blair Comments on Pyxis Oncology FY2027 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Equities researchers at William Blair issued their FY2027 earnings per share estimates for shares of Pyxis Oncology in a research report issued on Tuesday, March 18th. William Blair analyst A. Hsieh forecasts that the company will earn ($1.27) per share for the year. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.01. The company had revenue of $16.15 million during the quarter.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Wednesday, March 19th. Royal Bank of Canada reiterated an "outperform" rating and set a $8.00 price target on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Pyxis Oncology presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.20.

Remove Ads

Pyxis Oncology Stock Down 0.8 %

NASDAQ PYXS traded down $0.01 on Thursday, reaching $1.20. The stock had a trading volume of 355,338 shares, compared to its average volume of 743,081. Pyxis Oncology has a 12-month low of $0.99 and a 12-month high of $6.18. The stock has a fifty day moving average price of $1.32 and a two-hundred day moving average price of $2.33. The firm has a market capitalization of $73.91 million, a price-to-earnings ratio of -1.17 and a beta of 1.11.

Institutional Investors Weigh In On Pyxis Oncology

A number of hedge funds have recently bought and sold shares of the stock. LMR Partners LLP purchased a new stake in shares of Pyxis Oncology during the third quarter worth approximately $294,000. Intech Investment Management LLC acquired a new position in Pyxis Oncology during the 3rd quarter worth approximately $55,000. MetLife Investment Management LLC increased its position in shares of Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company's stock valued at $69,000 after purchasing an additional 5,484 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Pyxis Oncology in the 3rd quarter valued at $1,405,000. Finally, State Street Corp lifted its position in shares of Pyxis Oncology by 28.0% during the 3rd quarter. State Street Corp now owns 951,251 shares of the company's stock worth $3,491,000 after purchasing an additional 208,344 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.